Istituto di Ematologia "L. e A. Seràgnoli", Bologna, Italy.
Curr Hematol Malig Rep. 2011 Dec;6(4):241-4. doi: 10.1007/s11899-011-0098-6.
Most non-Hodgkin lymphomas (NHL) are of B-cell origin; only about 10% are T-cell or NK-cell lymphomas. The clinical features of T/NK-cell lymphomas differ from those of B-cell lymphomas: advanced stage and extranodal disease are more common and the prognosis is worse. Several studies have confirmed that 2-[fluorine-18]fluoro-2-deoxy-D-glucose (18FDG) uptake varies among different subtypes of lymphoma, a disparity that can be explained by the differences in histology, proliferation of tumor cells, and the ratio of viable tumor and reactive cells in the environment. These observations are based on investigation of B-cell lymphomas. Positron emission tomography (PET)/computed tomography (CT) was found to be useful both at staging and at measuring the therapeutic outcome after two to three cycles of chemotherapy (interim PET/CT). Several meta-analyses have confirmed the role of PET in evaluating the viability of the residual tumor mass after treatment. 18FDG-PET has been proved to have an excellent negative predictive value. Conversely, only a few studies have investigated the role of FDG-PET in T/NK-cell lymphomas. This paper summarizes the current information regarding the potential use of PET/CT in patients with T-cell lymphoma.
大多数非霍奇金淋巴瘤（NHL）来源于 B 细胞，仅有约 10%为 T 细胞或 NK 细胞淋巴瘤。T/NK 细胞淋巴瘤的临床特征与 B 细胞淋巴瘤不同：晚期和结外疾病更为常见，预后更差。几项研究证实，不同类型的淋巴瘤摄取 2-[氟-18]氟代-2-脱氧-D-葡萄糖（18FDG）的情况存在差异，这种差异可以用肿瘤细胞的组织学、增殖和肿瘤细胞与环境中反应性细胞的比例的差异来解释。这些观察结果基于对 B 细胞淋巴瘤的研究。正电子发射断层扫描（PET）/计算机断层扫描（CT）在分期和评估两个或三个化疗周期后的治疗效果（中期 PET/CT）方面都被证明是有用的。几项荟萃分析证实了 PET 在评估治疗后残留肿瘤活性方面的作用。18FDG-PET 具有出色的阴性预测价值。相反，只有少数研究探讨了 FDG-PET 在 T/NK 细胞淋巴瘤中的作用。本文总结了目前关于 PET/CT 在 T 细胞淋巴瘤患者中的潜在应用的信息。
